F

Fluoguide AS
STO:FLUO

Watchlist Manager
Fluoguide AS
STO:FLUO
Watchlist
Price: 35.85 SEK 5.6% Market Closed
Market Cap: 488.3m SEK
Have any thoughts about
Fluoguide AS?
Write Note

Fluoguide AS
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Fluoguide AS
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
F
Fluoguide AS
STO:FLUO
Short-Term Debt
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Short-Term Debt
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Short-Term Debt
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Short-Term Debt
€422.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Short-Term Debt
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Short-Term Debt
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Fluoguide AS
Glance View

Market Cap
444.9m SEK
Industry
Biotechnology

FluoGuide A/S engages in the development of surgical solutions to reduce suffering for the patient and increase the likelihood of cure; as well as reducing costs for the health care system. The firm develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue.

FLUO Intrinsic Value
39.2 SEK
Undervaluation 9%
Intrinsic Value
Price
F

See Also

What is Fluoguide AS's Short-Term Debt?
Short-Term Debt
0 DKK

Based on the financial report for Dec 31, 2023, Fluoguide AS's Short-Term Debt amounts to 0 DKK.

Back to Top